HYPERBARIC OXYGEN THERAPY IS CLINICALLY EFFECTIVE FOR REFRACTORY VIRUS-ASSOCIATED HEMORRHAGIC CYSTITIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
(Abstract release date: 05/19/16)
EHA Library. Suzuki Y. 06/09/16; 133079; E1530
Dr. Yuzo Suzuki
Contributions
Contributions
Abstract
Abstract: E1530
Type: Eposter Presentation
Background
Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been frequently associated with viral infection of adenovirus (ADV), BK virus (BKV), JC virus (JCV) or another viruses. Antiviral drugs are of limited efficacy, and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients, but efficacy and safety of HBO for HC has not been evaluated sufficiently.
Aims
To clarify the efficacy and safety of HBO therapy for viral HC, we retrospectively evaluated clinical data during the therapy.
Methods
In 199 cases of allogeneic HSCT from September 1994 to November 2015, we experienced 8 cases of refractory viral HC by ADV or JCV. We evaluated the effectiveness of HBO therapy in 8 patients with refractory HC after allogeneic HSCT at our institution.
Results
All 8 patients had macroscopic hematuria associated ADV or BKV infections. Patients received 100% oxygen in a hyperbaric chamber at 2.1 atmospheres for 90-120 min per day, 5 days per week, with 13 median treatments (range, 10-16). The 5 of 8 patients (62.5%) showed complete resolution of hematuria in 7 days. The pain during urination disappeared in all 8 patients (100%) in 5 days. Urinary DNA titers of ADV or BKV declined after HBO. Patients who started on HBO earlier after diagnosis of HC responded sooner and better than those who did on HBO later. Interestingly, 3 of 8 patients (37.5%) showed dramatic recovery from refractory acute graft versus host disease (GVHD) symptom accompanied by thrombotic microangiopathy (TMA), after HBO therapy for refractory virus-associated HC.
Conclusion
HBO therpy was generally well tolerated, and proved to be a reliable option for refractory viral HC cases to manage their condition.
Session topic: E-poster
Keyword(s): Allo-SCT, Hemorrhagic cystitis, Infection
Type: Eposter Presentation
Background
Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been frequently associated with viral infection of adenovirus (ADV), BK virus (BKV), JC virus (JCV) or another viruses. Antiviral drugs are of limited efficacy, and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients, but efficacy and safety of HBO for HC has not been evaluated sufficiently.
Aims
To clarify the efficacy and safety of HBO therapy for viral HC, we retrospectively evaluated clinical data during the therapy.
Methods
In 199 cases of allogeneic HSCT from September 1994 to November 2015, we experienced 8 cases of refractory viral HC by ADV or JCV. We evaluated the effectiveness of HBO therapy in 8 patients with refractory HC after allogeneic HSCT at our institution.
Results
All 8 patients had macroscopic hematuria associated ADV or BKV infections. Patients received 100% oxygen in a hyperbaric chamber at 2.1 atmospheres for 90-120 min per day, 5 days per week, with 13 median treatments (range, 10-16). The 5 of 8 patients (62.5%) showed complete resolution of hematuria in 7 days. The pain during urination disappeared in all 8 patients (100%) in 5 days. Urinary DNA titers of ADV or BKV declined after HBO. Patients who started on HBO earlier after diagnosis of HC responded sooner and better than those who did on HBO later. Interestingly, 3 of 8 patients (37.5%) showed dramatic recovery from refractory acute graft versus host disease (GVHD) symptom accompanied by thrombotic microangiopathy (TMA), after HBO therapy for refractory virus-associated HC.
Conclusion
HBO therpy was generally well tolerated, and proved to be a reliable option for refractory viral HC cases to manage their condition.
Session topic: E-poster
Keyword(s): Allo-SCT, Hemorrhagic cystitis, Infection
Abstract: E1530
Type: Eposter Presentation
Background
Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been frequently associated with viral infection of adenovirus (ADV), BK virus (BKV), JC virus (JCV) or another viruses. Antiviral drugs are of limited efficacy, and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients, but efficacy and safety of HBO for HC has not been evaluated sufficiently.
Aims
To clarify the efficacy and safety of HBO therapy for viral HC, we retrospectively evaluated clinical data during the therapy.
Methods
In 199 cases of allogeneic HSCT from September 1994 to November 2015, we experienced 8 cases of refractory viral HC by ADV or JCV. We evaluated the effectiveness of HBO therapy in 8 patients with refractory HC after allogeneic HSCT at our institution.
Results
All 8 patients had macroscopic hematuria associated ADV or BKV infections. Patients received 100% oxygen in a hyperbaric chamber at 2.1 atmospheres for 90-120 min per day, 5 days per week, with 13 median treatments (range, 10-16). The 5 of 8 patients (62.5%) showed complete resolution of hematuria in 7 days. The pain during urination disappeared in all 8 patients (100%) in 5 days. Urinary DNA titers of ADV or BKV declined after HBO. Patients who started on HBO earlier after diagnosis of HC responded sooner and better than those who did on HBO later. Interestingly, 3 of 8 patients (37.5%) showed dramatic recovery from refractory acute graft versus host disease (GVHD) symptom accompanied by thrombotic microangiopathy (TMA), after HBO therapy for refractory virus-associated HC.
Conclusion
HBO therpy was generally well tolerated, and proved to be a reliable option for refractory viral HC cases to manage their condition.
Session topic: E-poster
Keyword(s): Allo-SCT, Hemorrhagic cystitis, Infection
Type: Eposter Presentation
Background
Late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) has been frequently associated with viral infection of adenovirus (ADV), BK virus (BKV), JC virus (JCV) or another viruses. Antiviral drugs are of limited efficacy, and the optimal treatment for HC has not yet been established. Hyperbaric oxygen (HBO) may benefit these patients, but efficacy and safety of HBO for HC has not been evaluated sufficiently.
Aims
To clarify the efficacy and safety of HBO therapy for viral HC, we retrospectively evaluated clinical data during the therapy.
Methods
In 199 cases of allogeneic HSCT from September 1994 to November 2015, we experienced 8 cases of refractory viral HC by ADV or JCV. We evaluated the effectiveness of HBO therapy in 8 patients with refractory HC after allogeneic HSCT at our institution.
Results
All 8 patients had macroscopic hematuria associated ADV or BKV infections. Patients received 100% oxygen in a hyperbaric chamber at 2.1 atmospheres for 90-120 min per day, 5 days per week, with 13 median treatments (range, 10-16). The 5 of 8 patients (62.5%) showed complete resolution of hematuria in 7 days. The pain during urination disappeared in all 8 patients (100%) in 5 days. Urinary DNA titers of ADV or BKV declined after HBO. Patients who started on HBO earlier after diagnosis of HC responded sooner and better than those who did on HBO later. Interestingly, 3 of 8 patients (37.5%) showed dramatic recovery from refractory acute graft versus host disease (GVHD) symptom accompanied by thrombotic microangiopathy (TMA), after HBO therapy for refractory virus-associated HC.
Conclusion
HBO therpy was generally well tolerated, and proved to be a reliable option for refractory viral HC cases to manage their condition.
Session topic: E-poster
Keyword(s): Allo-SCT, Hemorrhagic cystitis, Infection
{{ help_message }}
{{filter}}